Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,627 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,360 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,368)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02425891 | A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130) | completed | Phase 3 | 902 | Hoffmann-La RocheINDUSTRY | 40 | Jul 19, 2022 | clinicaltrials |
| NCT02574455 | Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC)(ASCENT) | completed | Phase 3 | 529 | Gilead SciencesINDUSTRY | 7 |
| Jun 15, 2022 |
| clinicaltrials |
| NCT00003857 | Radiation Therapy With or Without Optional Tamoxifen in Treating Women With Ductal Carcinoma in Situ | completed | Phase 3 | 636 | Radiation Therapy Oncology GroupNETWORK | 2 | May 25, 2022 | clinicaltrials |
| NCT01517802 | A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate | completed | Phase 3 | 32 | Janssen Research & Development, LLCINDUSTRY | 7 | May 10, 2022 | clinicaltrials |
| NCT01095003 | Trial of Vinflunine Plus Capecitabine in Advanced Breast Cancer | completed | Phase 3 | 770 | Pierre Fabre MedicamentINDUSTRY | 21 | Apr 28, 2022 | clinicaltrials |
| NCT02546934 | ABX Plus Cisplatin Versus Gemcitabine Plus Cisplatin in Triple Negative Breast Cancer (TNBC)(TNBC) | completed | Phase 3 | 254 | Fudan UniversityOTHER | 1 | Apr 22, 2022 | clinicaltrials |
| NCT00887536 | A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer | completed | Phase 3 | 1,613 | NSABP Foundation IncNETWORK | 2 | Apr 20, 2022 | clinicaltrials |
| NCT02336750 | Adding Mirtazapine to Dexamethasone and Aprepitant for Delayed Emesis | completed | Phase 3 | 212 | Fudan UniversityOTHER | 1 | Apr 20, 2022 | clinicaltrials |
| NCT01702571 | A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment | completed | Phase 3 | 2,185 | Hoffmann-La RocheINDUSTRY | 43 | Apr 4, 2022 | clinicaltrials |
| NCT03764943 | Immunonutrition and Carbohydrate Loading Strategies in Breast Reconstruction | completed | Phase 3 | 125 | University of Wisconsin, MadisonOTHER | 1 | Mar 29, 2022 | clinicaltrials |
| NCT02643420 | SPI-2012 vs Pegfilgrastim in the Management of Neutropenia in Participants With Breast Cancer With Docetaxel and Cyclophosphamide (ADVANCE)(ADVANCE) | completed | Phase 3 | 406 | Spectrum Pharmaceuticals, IncINDUSTRY | 3 | Mar 2, 2022 | clinicaltrials |
| NCT02953340 | SPI-2012 vs Pegfilgrastim in Management of Neutropenia in Breast Cancer Participants With Docetaxel and Cyclophosphamide | completed | Phase 3 | 237 | Spectrum Pharmaceuticals, IncINDUSTRY | 6 | Mar 2, 2022 | clinicaltrials |
| NCT02472964 | Study of Efficacy and Safety of Myl1401O + Taxane vs Herceptin©+ Taxane for 1st Line, Met. Br. Ca.(HERiTAge) | completed | Phase 3 | 500 | Mylan Inc.INDUSTRY | 15 | Feb 14, 2022 | clinicaltrials |
| NCT00408863 | Livial Intervention Following Breast Cancer; Efficacy, Recurrence and Tolerability Endpoints (LIBERATE)(COMPLETED)(P05885) | completed | Phase 3 | 3,148 | Organon and CoINDUSTRY | 0 | Feb 4, 2022 | clinicaltrials |
| NCT04951245 | Ultrasound-assisted CNSs Mapping Versus Dual-tracer-guided Sentinel Lymph Node Biopsy(UltraCars) | completed | Phase 3 | 330 | Guangdong Provincial People's HospitalOTHER | 1 | Jan 28, 2022 | clinicaltrials |
| NCT03556358 | Trial to Compare the Safety, Efficacy and Immunogenicity of TX05 With Herceptin® in HER2+ Early Breast Cancer | completed | Phase 3 | 809 | Tanvex BioPharma USA, Inc.INDUSTRY | 10 | Jan 14, 2022 | clinicaltrials |
| NCT02482753 | Trial of Chidamide in Combination With Exemestane in Patients With Advanced Breast Cancer | completed | Phase 3 | 365 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | Jan 12, 2022 | clinicaltrials |
| NCT02896855 | A Study to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel Versus Placebo + Trastuzumab + Docetaxel in Previously Untreated Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer(PUFFIN) | completed | Phase 3 | 243 | Hoffmann-La RocheINDUSTRY | 1 | Dec 16, 2021 | clinicaltrials |
| NCT02555657 | Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119) | completed | Phase 3 | 622 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Dec 10, 2021 | clinicaltrials |
| NCT00703326 | Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer | completed | Phase 3 | 1,144 | Eli Lilly and CompanyINDUSTRY | 23 | Dec 6, 2021 | clinicaltrials |
| NCT02468739 | Effect of GM1 in Prevention of Taxanes Induced Neurotoxicity in Operable Breast Cancer | completed | Phase 3 | 206 | Sun Yat-sen UniversityOTHER | 1 | Nov 4, 2021 | clinicaltrials |
| NCT03096847 | Study for Women and Men With Hormone-receptor Positive Locally Advanced or Metastatic Breast Cancer | completed | Phase 3 | 502 | Novartis PharmaceuticalsINDUSTRY | 1 | Oct 11, 2021 | clinicaltrials |
| NCT00078832 | Anastrozole in Preventing Breast Cancer in Postmenopausal Women at Increased Risk of Breast Cancer(IBIS II) | completed | Phase 3 | 3,864 | Queen Mary University of LondonOTHER | 14 | Oct 6, 2021 | clinicaltrials |
| NCT04059809 | Photobiomodulation for Breast Cancer Radiodermatitis | completed | Phase 2 / Phase 3 | 48 | AC Camargo Cancer CenterOTHER | 1 | Aug 13, 2021 | clinicaltrials |
| NCT03079219 | Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Chinese Breast Cancer Patients | completed | Phase 3 | 120 | CCTUOTHER | 1 | Jul 28, 2021 | clinicaltrials |
| NCT00127205 | S0307 Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer. | completed | Phase 3 | 6,097 | SWOG Cancer Research NetworkNETWORK | 0 | Jul 2, 2021 | clinicaltrials |
| NCT04075058 | Hypofractionated Radiation Therapy in Patients With Breast Cancer(HRBC) | completed | Phase 3 | 1,070 | Post Graduate Institute of Medical Education and Research, ChandigarhOTHER | 1 | Jun 23, 2021 | clinicaltrials |
| NCT00878709 | Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer(ExteNET) | completed | Phase 3 | 2,840 | Puma Biotechnology, Inc.INDUSTRY | 40 | Jun 11, 2021 | clinicaltrials |
| NCT02518191 | Effects of GnRHa on Ovarian Function Against Chemotherapy-induced-gonadotoxicity | completed | Phase 3 | 345 | Xiangyun ZongOTHER | 1 | Jun 11, 2021 | clinicaltrials |
| NCT01492101 | The BEACON Study (Breast Cancer Outcomes With NKTR-102)(BEACON) | completed | Phase 3 | 852 | Nektar TherapeuticsINDUSTRY | 11 | Jun 1, 2021 | clinicaltrials |
| NCT04718324 | PREMs on PROMs in Breast Disease (PREMs_PROMs)(PREMs_PROMs) | completed | Phase 3 | 230 | Uppsala UniversityOTHER | 1 | May 17, 2021 | clinicaltrials |
| NCT02872103 | Placebo-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy | completed | Phase 3 | 122 | EVIVE BiotechnologyINDUSTRY | 1 | May 5, 2021 | clinicaltrials |
| NCT00004067 | Doxorubicin and Cyclophosphamide Plus Paclitaxel With or Without Trastuzumab in Treating Women With Node-Positive Breast Cancer That Overexpresses HER2 | completed | Phase 3 | 2,130 | NSABP Foundation IncNETWORK | 2 | Apr 29, 2021 | clinicaltrials |
| NCT02324088 | Interest of Maintenance Chemotherapy After Induction Treatment for Inflammatory Breast Cancer(PEGASE07) | completed | Phase 3 | 174 | UNICANCEROTHER | 0 | Feb 21, 2021 | clinicaltrials |
| NCT01150513 | Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer | completed | Phase 2 / Phase 3 | 320 | Chinese Academy of Medical SciencesOTHER | 1 | Feb 9, 2021 | clinicaltrials |
| NCT00544765 | Docetaxel, Doxorubicin and Cyclophosphamide Versus Vinorelbine and Capecitabine in Patients Not Sufficiently / Sufficiently Responding as Preoperative Treatment of Locally Advanced or Operable Primary Breast Cancer(GeparTrio) | completed | Phase 3 | 2,014 | GBG Forschungs GmbHOTHER | 0 | Feb 4, 2021 | clinicaltrials |
| NCT01690702 | Study of Nab-Paclitaxel in High Risk Early Breast Cancer(GAIN-2) | completed | Phase 3 | 2,886 | GBG Forschungs GmbHOTHER | 1 | Feb 2, 2021 | clinicaltrials |
| NCT01591811 | Prospective Trial of Two Prone Breast Radiotherapy Techniques With Randomization to Concurrent Versus Weekly Boost | completed | Phase 3 | 433 | NYU Langone HealthOTHER | 1 | Jan 19, 2021 | clinicaltrials |
| NCT00075764 | S0226 Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast Cancer | completed | Phase 3 | 695 | SWOG Cancer Research NetworkNETWORK | 2 | Jan 13, 2021 | clinicaltrials |
| NCT03343145 | A Study to Evaluate the Efficacy, Safety and Immunogenicity of Leucostim® Versus Neupogen® in Breast Cancer Patients | completed | Phase 3 | 143 | Dong-A ST Co., Ltd.INDUSTRY | 1 | Dec 28, 2020 | clinicaltrials |
| NCT01940497 | A Study of the Safety of Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Early and Locally Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer(SCHEARLY) | completed | Phase 3 | 240 | Hoffmann-La RocheINDUSTRY | 1 | Nov 3, 2020 | clinicaltrials |
| NCT03165149 | Effect of a Topical Ketamine on Acute and Chronic Pain, Dose Finding | completed | Phase 2 / Phase 3 | 90 | Assiut UniversityOTHER | 1 | Nov 3, 2020 | clinicaltrials |
| NCT00080301 | Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer | completed | Phase 3 | 752 | R-PharmINDUSTRY | 22 | Nov 2, 2020 | clinicaltrials |
| NCT00082433 | Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer | completed | Phase 3 | 1,221 | R-PharmINDUSTRY | 29 | Nov 2, 2020 | clinicaltrials |
| NCT00309491 | Randomized Study Comparing Tamoxifen vs. Tamoxifen + Aminoglutethimide in Postmenopausal Receptor-positive Patients | completed | Phase 3 | 2,021 | Austrian Breast & Colorectal Cancer Study GroupNETWORK | 0 | Oct 19, 2020 | clinicaltrials |
| NCT00309569 | Randomized Study Comparing Pre- and Postoperative vs. Conventional Adjuvant Treatment in Receptor-negative Patients | completed | Phase 3 | 429 | Austrian Breast & Colorectal Cancer Study GroupNETWORK | 0 | Oct 14, 2020 | clinicaltrials |
| NCT04237090 | Feasibility of a Clinical Trial Comparing the Use of Cetirizine to Replace Diphenhydramine in the Prevention of Reactions Related to Paclitaxel(PREMED-F1) | completed | Phase 3 | 27 | Ciusss de L'Est de l'Île de MontréalOTHER | 1 | Oct 12, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Jul 19, 2022source: clinicaltrials